Janssen-cilag G.m.b.h

This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the treatment affects daily life, including fatigue and work productivity. The goal is to underst…